{"id":390927,"date":"2017-08-18T00:00:00","date_gmt":"2017-08-18T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/algoim0046-2018-biopharma-atopic-dermatitis-atopic-eczema-treatment-algorithms-claims-data-analysis-pediatric-us-2018\/"},"modified":"2026-05-07T23:24:34","modified_gmt":"2026-05-07T23:24:34","slug":"algoim0046-2018-biopharma-atopic-dermatitis-atopic-eczema-treatment-algorithms-claims-data-analysis-pediatric-us-2018","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/algoim0046-2018-biopharma-atopic-dermatitis-atopic-eczema-treatment-algorithms-claims-data-analysis-pediatric-us-2018\/","title":{"rendered":"Atopic Dermatitis\/Atopic Eczema | Treatment Algorithms: Claims Data Analysis | Pediatric | US | 2018"},"content":{"rendered":"<p>Atopic dermatitis (<abbr title=\"atopic dermatitis\">AD<\/abbr>) is a chronic, pediatric-onset, inflammatory skin disease marked principally by pruritus and eczema. Topical agents (e.g., corticosteroids) are the mainstays of prescription <abbr title=\"atopic dermatitis\">AD<\/abbr> treatment, and systemic immunomodulators may be used to treat topical-refractory cases, although risk-averse pediatricians may avoid more-potent medications. Recent entrants from Pfizer (i.e., Eucrisa) and Sanofi\/Regeneron (i.e., Dupixent) offer a new, nonsteroidal topical option and a biologic for topical-refractory adult patients, respectively. This content explores how new therapies have fared in pediatric patients\u00a0and provides context for new players seeking to capitalize on the unmet needs in <abbr title=\"atopic dermatitis\">AD<\/abbr>.<\/p>\n<p>\u00a0<\/p>\n<p><strong>QUESTIONS ANSWERED<\/strong><\/p>\n<ul>\n<li>What patient share do key therapies and brands garner by line of therapy in newly diagnosed pediatric <abbr title=\"atopic dermatitis\">AD<\/abbr>\u00a0patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed pediatric <abbr title=\"atopic dermatitis\">AD<\/abbr> patients?<\/li>\n<li>How have Dupixent and Eucrisa been integrated into the treatment algorithm?<\/li>\n<li>What proportion of pediatric <abbr title=\"atopic dermatitis\">AD<\/abbr> patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?<\/li>\n<li>What percentage of pediatric <abbr title=\"atopic dermatitis\">AD<\/abbr> patients are treated with monotherapy versus combination therapy? What are the most widely used combination therapies?<\/li>\n<li>What are the product-level compliance and persistency rates among drug-treated pediatric patients with <abbr title=\"atopic dermatitis\">AD<\/abbr>?<\/li>\n<\/ul>\n<p><strong>PRODUCT DESCRIPTION<\/strong><\/p>\n<p><em>Treatment Algorithms: Claims Data Analysis<\/em> provides detailed analysis of brand usage across different lines of therapy using real-world, patient-level claims data so that clients can accurately assess their source of business and quantify areas of opportunity for increasing their brand share.<\/p>\n<p><strong>GEOGRAPHIES<\/strong><\/p>\n<ul>\n<li>United States<\/li>\n<\/ul>\n<p><strong>REAL-WORLD DATA<\/strong><\/p>\n<p>Longitudinal patient-level claims data analysis<\/p>\n<p><strong>KEY DRUGS COVERED<\/strong><\/p>\n<p>Dupixent, Eucrisa, Protopic, Elidel, cyclosporine, methotrexate, azathioprine, mycophenolate mofetil, key topical corticosteroids<\/p>\n<p><strong>KEY ANALYSIS PROVIDED<\/strong><\/p>\n<ul>\n<li>Brand use across a longitudinal patient sample.<\/li>\n<li>Newly diagnosed patient analysis.<\/li>\n<li>Treatment initiation and progression.<\/li>\n<li>Line of therapy analysis.<\/li>\n<li>Combination therapy analysis.<\/li>\n<li>Source of business for recently treated patients.<\/li>\n<li>Persistency and compliance analysis.<\/li>\n<li>Product-level patient flowcharts.<\/li>\n<\/ul>\n","protected":false},"template":"","class_list":["post-390927","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-product-treatment-algorithms-claims-data-analysis","biopharma-geography-us","biopharma-date-890"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390927","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390927\/revisions"}],"predecessor-version":[{"id":394051,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390927\/revisions\/394051"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390927"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}